Arcus Biosciences Announces Results of 2026 Annual Meeting of Stockholders

On June 11, 2026, Arcus Biosciences, Inc. held its Annual Meeting of Stockholders to vote on three key proposals. First, stockholders elected four Class II directors—Dietmar Berger, M.D., Ph.D., David Lacey, M.D., Nicole Lambert, and Johanna Mercier—to serve until the 2029 Annual Meeting. All nominees were successfully elected, with Nicole Lambert receiving the highest number of 'For' votes at over 92.6 million. Second, the stockholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 112,905,582 votes in favor. Finally, stockholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the Proxy Statement, receiving approximately 94.9 million votes in support. The filing confirms the results of these standard governance matters and does not disclose any new clinical data, partnerships, or material financial changes.